zalutumumab

mAbexperimental

Zalutumumab is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. — Wikipedia

Clinical trial activity

10 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
10
Phase 3
2
Phase 4
0

Earliest trial started Dec 1, 2003 (NCT00093041)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2f8
  • 2f8
  • humax-egfr
  • humax-egfr, 2f8
  • zalutumumab
  • zalutumumab
  • zalutumumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01449357Phase 2Sep 29, 2011Genmab, University of South Florida
NCT01054625Phase 1/Phase 2 (Phase 2)Mar 1, 2010Genmab, Université catholique de Louvain
NCT00707655Phase 1/Phase 2 (Phase 2)Sep 1, 2008Genmab
NCT00677924Phase 1/Phase 2 (Phase 2)Apr 1, 2008Genmab
NCT00542308Phase 2Jan 1, 2008Genmab
NCT00496652Phase 3Nov 1, 2007Danish Head and Neck Cancer Group
NCT00460551Phase 2Apr 1, 2007Genmab
NCT00401401Phase 1/Phase 2 (Phase 2)Dec 1, 2006Genmab, Université catholique de Louvain
NCT00382031Phase 3Nov 1, 2006Genmab
NCT00093041Phase 1/Phase 2 (Phase 2)Dec 1, 2003Genmab
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GenmabFor profit9922003
Université catholique de LouvainAcademic/Hospital2012006
Danish Head and Neck Cancer GroupAcademic/Hospital1112007
University of South FloridaAcademic/Hospital1012011
4 organizations
Page 1 / 1